In ‘Hypertension Management in Hypercortisolism,’our panel explores the clinical implications of emerging data on hypercortisolism and outline a forward-looking approach to hypertension management. The panelists emphasize that recent findings from studies such as MOMENTUM and CATALYST should prompt immediate changes in clinical practice, particularly the routine use of simple screening tools like the dexamethasone suppression test in patients with resistant hypertension and difficult-to-control diabetes.

The expert panel highlights the importance of moving beyond traditional medical training that has framed hypercortisolism as rare and easily identifiable by classic features. Instead, faculty encourage clinicians to recognize hypercortisolism as a more common, heterogeneous condition that often presents without overt physical signs but contributes significantly to cardiometabolic disease.

Importantly, the discussion expands to a broader paradigm shift in cardiovascular care, one that prioritizes identifying underlying drivers of disease rather than solely managing symptoms. Drawing parallels to advances in heart failure, the panelists describe a future in which hypertension and metabolic disorders are more precisely phenotyped, enabling targeted and potentially disease-modifying interventions. Overall, the expert faculty underscore the importance of integrating screening, diagnosis, and emerging therapeutics into a more personalized, mechanism-driven approach to patient care.

Our next episode, ‘Hypercortisolism Treatment and Care Pathways,’ the panelists explore treatment approaches for hypercortisolism following diagnosis. The panel highlights the importance of multidisciplinary care and individualized management strategies.